| These highlights do not include all the information needed to use HERCEPTIN HYLECTA safely and effectively. See full prescribing information for HERCEPTIN HYLECTA. HERCEPTIN HYLECTA® (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use Initial U.S. Approval: 2019 | Genentech, Inc. | Roche Singapore Technical Operations Pte. Ltd | Roche Diagnostics | Roche Diagnostics GmbH | F. Hoffmann-La Roche AG | Genentech, Inc. (Oceanside) | 20260529 | 11 |
| These highlights do not include all the information needed to use PHESGO safely and effectively. See full prescribing information for PHESGO. PHESGO ® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 2020 | Genentech, Inc. | Roche Diagnostics GmbH | F. Hoffmann-La Roche AG | Genentech, Inc. (Oceanside) | Roche Singapore Technical Operations Pte. Ltd | 20260521 | 17 |
| These highlights do not include all the information needed to use TECENTRIQ HYBREZA safely and effectively. See full prescribing information for TECENTRIQ HYBREZA. TECENTRIQ HYBREZA ® (atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use Initial U.S. Approval: 2024 | Genentech, Inc. | Roche Diagnostics GmbH | Genentech, Inc. (Oceanside) | F. Hoffmann-La Roche AG | 20260520 | 7 |
| These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023 | argenx US | Patheon Italia SpA | Avid Bioservices Inc. | Vetter RVS | Lonza Biologics Portsmouth | Catalent Indiana, LLC | 20260513 | 12 |
| These highlights do not include all the information needed to use OPDIVO QVANTIG safely and effectively. See full prescribing information for OPDIVO QVANTIG. OPDIVO QVANTIG™ (nivolumab and hyaluronidase-nvhy) injection, for subcutaneous use. Initial U.S. Approval: 2024 | E.R. Squibb & Sons, L.L.C. | Bioreliance Ltd. | 20260512 | 8 |
| These highlights do not include all the information needed to use OCREVUS ZUNOVO safely and effectively. See full prescribing information for OCREVUS ZUNOVO. OCREVUS ZUNOVO ® (ocrelizumab and hyaluronidase-ocsq) injection, for subcutaneous use Initial U.S. Approval: 2024 | Genentech, Inc. | Roche Diagnostics GmbH | F. Hoffmann-La Roche AG | Genentech, Inc. (Oceanside) | Roche Diagnostics | 20260427 | 9 |
| These highlights do not include all the information needed to use RYBREVANT FASPRO safely and effectively. See full prescribing information for RYBREVANT FASPRO. RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) injection, for subcutaneous use Initial U.S. Approval: 2025 | Janssen Biotech, Inc. | Samsung Biologics Co., Ltd. | Janssen Sciences Ireland UC | Jannsen Biologics B.V. | Cilag AG | Bioreliance Corporation | Avid Bioservices Inc. | 20260218 | 4 |
| These highlights do not include all the information needed to use DARZALEX FASPRO safely and effectively. See full prescribing information for DARZALEX FASPRO. DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use Initial U.S. Approval: 2020 | Janssen Biotech, Inc. | Eurofins Lancaster Laboratories, Inc | Charles River Laboratories | Catalent Indiana, LLC | Biogen (Denmark) Manufacturing ApS | Jannsen Biologics B.V. | Cilag AG | Janssen Vaccines Corp. | Janssen Sciences Ireland UC | Bioreliance Corporation | 20260211 | 31 |
| These highlights do not include all the information needed to use HYQVIA ® safely and effectively. See full prescribing information for HYQVIA. HYQVIA ® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] Solution, for subcutaneous administration Initial U.S. Approval: 2014 | Takeda Pharmaceuticals America, Inc. | Baxalta Belgium Manufacturing SA | Catalent Indiana, LLC | Takeda Manufacturing Austria AG | Baxalta US Inc. | 20260204 | 22 |
| These highlights do not include all the information needed to use RITUXAN HYCELA safely and effectively. See full prescribing information for RITUXAN HYCELA. RITUXAN HYCELA ® (rituximab and hyaluronidase human) injection, for subcutaneous use Initial U.S. Approval: 2017 | Genentech, Inc. | F. Hoffmann-La Roche AG | Roche Diagnostics GmbH | Genentech, Inc | 20251215 | 21 |
| These highlights do not include all the information needed to use HYLENEX recombinant safely and effectively. See full prescribing information for HYLENEX recombinant. HYLENEX recombinant (hyaluronidase) injection for infiltration use, for interstitial use, for intramuscular use, for intraocular use, for peribulbar use, retrobulbar use, for soft tissue use or for subcutaneous use Initial U.S. Approval: 2005 | Antares Pharma, Inc. | Patheon Manufacturing Services LLC | 20241111 | 11 |
| HYLENEX® RECOMBINANT 1mL (HYALURONIDASE HUMAN INJECTION) 150 USP UNITS/mL 1mL VIAL | HF Acquisition Co LLC, DBA HealthFirst | 20210604 | 1 |